Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.34 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.34 |
| ▸ | CDK2 | P24941 | 8/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679993 | 0.92 | MTOR (0.41) | MTORPIK3CAPIK3CDPIK3CGRPTOR | |
| SCHEMBL2679994 | 0.92 | MTOR (0.41) | MTORPIK3CAPIK3CDPIK3CGRPTOR | |
| SCHEMBL10234674 | 0.92 | MTOR (0.41) | MTORPIK3CAPIK3CDPIK3CGRPTOR | |
| SCHEMBL10234867 | 0.91 | RAB9A (0.38) | MTORPIK3CAPIK3CDPIK3CGRPTOR | |
| SCHEMBL10238033 | 0.91 | CHEK1 (0.43) | MTORCHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL10238350 | 0.90 | CHEK1 (0.43) | MTORPIK3CAPIK3CDPIK3CGRPTOR | |
| SCHEMBL10234977 | 0.90 | MTOR (0.44) | MTORPIK3CAPIK3CDPIK3CGRPTOR | |
| SCHEMBL7887431 | 0.90 | PIK3CA (0.43) | MTORPIK3CAPIK3CDJAK1JAK3 | |
| SCHEMBL10238074 | 0.90 | MTOR (0.34) | MTORPIK3CAPIK3CDPIK3CGRPTOR | |
| SCHEMBL10234896 | 0.90 | THRB (0.36) | MTORPIK3CAPIK3CDPIK3CGRPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 34/4885PIK3CD 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.